Alnylam Pharmaceuticals (NASDAQ:ALNY) has received a mix of bullish and indifferent analyst ratings over the last quarter, with no bearish ratings. The average 12-month price target among 20 analysts is $252.65, with a high of $405.00 and a low of $170.00. This target has increased by 1.47% from the previous target of $249.00. Analysts rate stocks based on research and provide guidance which investors should use with caution, as analysts are also human and can only offer opinions.